Waters Corporation (WAT)

Environment story

Waters demonstrates moderate environmental performance with undisclosed comprehensive Scope 1, 2, and 3 emissions data. The company has not publicly committed to a specific net-zero target year prior to 2045, triggering a 15-point deduction. No major resource-extraction or water-contamination controversies identified in filed documents. However, absence of verified decarbonization infrastructure investments and reliance on unspecified mitigation strategies limits the score. The Xevo TQ Absolute XR system claims 50% reductions in power and nitrogen consumption, but this appears to be relative competitor comparison rather than verified absolute operational decarbonization. Greenwashing risk is elevated due to lack of granular Scope 3 disclosure (product-use emissions from analytical instruments in pharmaceutical/clinical labs likely represent >70% of footprint but are not quantified).

Social story

Waters scores moderately on social metrics with documented CEO-to-median-worker pay ratio of 153:1 (below 200:1 threshold, no deduction applied). Board and leadership diversity composition not fully disclosed in proxy; new director Claire M. Fraser brings genomics/diagnostics expertise but overall gender and racial diversity percentages in executive ranks remain undisclosed. No documented union-suppression activity, strikes, or NLRB complaints in the filing period. Supply-chain labor practices not comprehensively audited; company operates globally with ~16,000 employees post-BD acquisition but specific human-rights due diligence for cobalt, lithium, or other high-risk minerals not detailed. Plant safety metrics (turnover, injury rates) not disclosed in available documents. TA Instruments and Wyatt Technology acquisitions integrated with no reported labor disruptions.

Governance story

Waters demonstrates sound governance structure with 11-member Board, post-BD acquisition expansion. Board independence appears strong (all committee members noted as independent under NYSE standards and company criteria); specific independence percentage not quantified in filing but committee descriptions indicate >75% independence. No dual-class share structure disclosed; single class of common stock, $0.01 par value. Lobbying expenditures and specific regulatory proceedings not detailed in provided documents. Company subject to SEC compliance (Form 10-K filed, SOX 404(b) attestation by registered public accounting firm completed with no material weaknesses identified as of December 31, 2025). No antitrust, major consumer-safety, or financial-fraud proceedings mentioned. Compensation structure includes equity incentives (PSUs, RSUs, stock options) aligned with performance; 153:1 CEO pay ratio demonstrates moderation. Board committees include Audit & Finance (16 meetings in 2025), Compensation, Nominating & Corporate Governance, and Science & Technology, with active oversight documented.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Waters Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Waters Corporation in the app for interactive charts and portfolio building.

More in Healthcare